Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies

被引：33

作者：

Pulanco, Marc C. ^{[1
]}

Madsen, Anne T. ^{[1
,2
]}

Tanwar, Ankit ^{[1
,3
]}

Corrigan, Devin T. ^{[1
]}

Zang, Xingxing ^{[1
,2
,3
,4
]}

机构：

[1] Albert Einstein Coll Med, Dept Microbiol & Immunol, New York, NY 10461 USA

[2] Albert Einstein Coll Med, Dept Urol, New York, NY 10461 USA

[3] Albert Einstein Coll Med, Dept Oncol, New York, NY 10461 USA

[4] Albert Einstein Coll Med, Dept Med, New York, NY 10461 USA

来源：

CELLULAR & MOLECULAR IMMUNOLOGY | 2023年 / 20卷 / 07期

关键词：

B7; family; immune checkpoints; metabolic regulators; glycobiology; therapy resistance; T-CELL SURVIVAL; ANTIBODY TARGETING PD-1; BREAST-CANCER CELLS; BISPECIFIC ANTIBODY; ACQUIRED-RESISTANCE; LUNG-CANCER; B7; FAMILY; PROGRAMMED DEATH-1; ANTI-PD-1; THERAPY; MONOCLONAL-ANTIBODY;

D O I：

10.1038/s41423-023-01019-8

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The B7/CD28 families of immune checkpoints play vital roles in negatively or positively regulating immune cells in homeostasis and various diseases. Recent basic and clinical studies have revealed novel biology of the B7/CD28 families and new therapeutics for cancer therapy. In this review, we discuss the newly discovered KIR3DL3/TMIGD2/HHLA2 pathways, PD-1/PD-L1 and B7-H3 as metabolic regulators, the glycobiology of PD-1/PD-L1, B7x (B7-H4) and B7-H3, and the recently characterized PD-L1/B7-1 cis-interaction. We also cover the tumor-intrinsic and -extrinsic resistance mechanisms to current anti-PD-1/PD-L1 and anti-CTLA-4 immunotherapies in clinical settings. Finally, we review new immunotherapies targeting B7-H3, B7x, PD-1/PD-L1, and CTLA-4 in current clinical trials.

引用

页码：694 / 713

页数：20

共 50 条

[1] Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies
Marc C. Pulanco
Anne T. Madsen
Ankit Tanwar
Devin T. Corrigan
Xingxing Zang
Cellular & Molecular Immunology, 2023, 20 : 694 - 713
[2] THE B7 AND CD28 RECEPTOR FAMILIES
JUNE, CH
BLUESTONE, JA
NADLER, LM
THOMPSON, CB
IMMUNOLOGY TODAY, 1994, 15 (07): : 321 - 331
[3] POTENTIAL ROLES OF THE B7 AND CD28 RECEPTOR FAMILIES IN AUTOIMMUNITY AND IMMUNE EVASION
HARLAN, DM
ABE, R
LEE, KP
JUNE, CH
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1995, 75 (02): : 99 - 111
[4] The B7–CD28 superfamily
Arlene H. Sharpe
Gordon J. Freeman
Nature Reviews Immunology, 2002, 2 : 116 - 126
[5] Therapeutic opportunities in the B7/CD28 family of ligands and receptors
Carreno, BM
Carter, LL
Collins, M
CURRENT OPINION IN PHARMACOLOGY, 2005, 5 (04) : 424 - 430
[6] CD28/B7 costimulation: A review
Greenfield, EA
Nguyen, KA
Kuchroo, VK
CRITICAL REVIEWS IN IMMUNOLOGY, 1998, 18 (05) : 389 - 418
[7] SnapShot: B7/CD28 Costimulation
Paterson, Alison M.
Vanguri, Vijay K.
Sharpe, Arlene H.
CELL, 2009, 137 (05) : 974 - U346
[8] A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2
Xiao, Yanping
Freeman, Gordon J.
CLINICAL CANCER RESEARCH, 2015, 21 (10) : 2201 - 2203
[9] CD28/B7 regulation of autoimmune diabetes
Herold, KC
Lenschow, DJ
Bluestone, JA
IMMUNOLOGIC RESEARCH, 1997, 16 (01) : 71 - 84
[10] CD28/B7 regulation of autoimmune diabetes
Kevan C. Herold
Deborah J. Lenschow
Jeffrey A. Bluestone
Immunologic Research, 1997, 16 : 71 - 84

← 1 2 3 4 5 →